NCT07704892 — "A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)" trial site landscape

Public-registry site landscape for NCT07704892, “A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)”, a Metabolic Dysfunction-associated Steatohepatitis study sponsored by GlaxoSmithKline. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07704892 (registry record)
Study title	A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sponsor	GlaxoSmithKline
Condition(s)	Metabolic Dysfunction-associated Steatohepatitis
Phase	PHASE3
Listed sites	0

Patient-friendly overview of this study: eichor.com/study/NCT07704892.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07704892 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →